FIT Biotech is set to start a Phase III HIV vaccine trial

Finland-based FIT Biotech will begin recruiting 1,000 patients for a trial of its therapeutic HIV vaccine later this year. If successful the trial--which is due to last two to three years--will culminate in marketing applications to U.S. and European regulators. FIT Biotech thinks the vaccine can cut the viral load in patients with HIV, potentially reducing the need to use costly and arduous antiretrovirals. Article

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.